Allogene Therapeutics, Inc.
ALLO
$1.21
-$0.01-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -20.01% | 11.63% | |||
| Gross Profit | 20.01% | -11.63% | |||
| SG&A Expenses | -4.74% | -3.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.50% | 7.77% | |||
| Operating Income | 16.50% | -7.77% | |||
| Income Before Tax | 14.72% | -0.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.72% | 0.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.72% | 0.34% | |||
| EBIT | 16.50% | -7.77% | |||
| EBITDA | 17.33% | -8.44% | |||
| EPS Basic | 16.11% | 2.53% | |||
| Normalized Basic EPS | 20.07% | -1.52% | |||
| EPS Diluted | 16.11% | 2.53% | |||
| Normalized Diluted EPS | 20.07% | -1.52% | |||
| Average Basic Shares Outstanding | 1.66% | 2.27% | |||
| Average Diluted Shares Outstanding | 1.66% | 2.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||